1 / (placebo fracture risk -treatment fracture risk) for vertebral (VF), non-vertebral (NVF) and hip fractures (HF) were derived as a function of fracture risks and compliance rates associated with each therapy. Both drug costs and efficacies were adjusted to compliance rates. Relative risks and placebo incidences of each fracture type were obtained from the clinical trials, meta-analyses from NICE reviews, and costs were gathered from local price database. Annual compliance rates were taken from the literature (Willemijn, Cur Med Res Opin 2008;24:3217-22). RESULTS: Compared to each oral bisphosphonate (OB), ZOL generated the lowest clinical NNTs for all fracture sites. Under conservative compliant patient rate of 50% for weekly and 75% for monthly OBs, cost of treatment to prevent one fracture in 3 years was a30,625 (VF) and a160,400 (HF) for ZOL; a76,800 (VF) and a272,900 (HF) for branded alendronate; a75,825a (VF) and a269,325a (HF) for generic alendronate; a170,250 (VF) and a783,400 (HF) for risedronate; and a65,725 (VF) for ibandronate. Sensitivity analyses were performed. CONCLUSIONS: In the Turkish setting, compared to all OBs once-yearly administered ZOL was dominantly the most cost-effective treatment regardless of fracture type upto a level of 90% compliance with oral therapies.
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Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2 Novartis Sverige AB, Taby, Sweden, 3 Novartis Pharma AG, Basel, Switzerland OBJECTIVES: To evaluate the cost effectiveness of zoledronic acid 5 mg once yearly compared to generic alendronate in postmenopausal patients with osteoporosis. METHODS: A cost effectiveness model, based on the model used in the NICE appraisals of the cost effectiveness of osteoporosis treatments in postmenopausal women at increased risk of fracture, was adapted to the Danish setting. Lifetime costs and quality adjusted life years (QALYs) were calculated assuming five years of treatment. Relative risks of fracture protection were obtained from the HORIZON-PFT trial for zoledronic acid 5 mg, and from meta-analyses from NICE reviews for generic alendronate, assumed to be equal to branded alendronate. Compliance with zoledronic acid was assumed to be 100% (by definition of a once-yearly infusion) and sensitivity analyses were conducted for the compliance with generic alendronate, with decreased efficacy extrapolated from the relationship between compliance and probability of fracture (Siris, 2006) . Costs of fractures were taken from Danish cost studies and/or DRG cost lists and pharmacy costs of the medications were based on official list prices. Utilities were obtained from the literature. RESULTS: For patients 70 years old with a T-score of 2.5, zoledronic acid dominated generic alenronate when compliance with generic alendronate was 70% or lower. The dominating cost effectiveness of zoledronic acid over generic alendronate increased with decreased generic alendronate compliance, with incremental cost effectiveness ratios (ICERs) of between 5.077 DKK for 70% compliance and 48,202 DKK for 50% compliance. CONCLUSIONS: A single annual infusion of zoledronic acid 5 mg provides cost savings over daily generic alendronate, assuming a conservative real-life compliance of 70% for generic alendronate. Therefore, despite the availability of cheaper generics, their poor compliance results in cost savings for a more expensive alternative with better compliance. Further data is needed to make conclusions on longer term implications. Evaluate the cost-effectiveness of dabigatran etexilate compared with enoxaparin for the primary prophylaxis of venous thromboembolism (VTE) after total hip replacement (THR) or total knee replacement (TKR) in Spain. METHODS: A published cost-effectiveness model was adapted to the perspective of the Spanish National Health Service. Oral dabigatran etexilate 220 mg/day was compared with injectable enoxaparin 40 mg/day. The efficacy and safety of the treatments was determined from two pivotal phase III studies comparing these interventions. The model combined a decision tree for the peri-operative period (acute phase, 10 weeks) with a Markov model for long-term events (chronic phase, 60 years). The treatment patterns, consumption of resources and costs were based on quantitative (databases, patient registries, official statistics) and qualitative (systematic literature review, expert surveys) data sources for Spain. Univariate deterministic and probabilistic sensitivity analyses were performed. RESULTS: The study results suggest that overall outcomes do not differ significantly between dabigatran etexilate and enoxaparin. Mean Life years were 0.018 and 0.020 higher for dabigatran patients undergoing THR and TKR respectively; mean QALYs were 0.013 and 0.015 higher respectively. Mean overall costs were lower for dabigatran patients by a189 and a53 respectively. In the probabilistic sensitivity analysis, dabigatran etexilate was dominant for most of the one thousand simulations in THR. The probability that dabigatran is cost-effective at a threshold of a30,000/QALY was 99% in THR and 87% in TKR. In the deterministic sensitivity analysis, dabigatran was dominant versus enoxaparin in all scenarios in both THR and TKR. CONCLUSIONS: From the viewpoint of the Spanish NHS, primary prophylaxis with dabigatran etexilate (220 mg/day orally) has a lower cost than enoxaparin (40 mg/day subcutaneously) after THR and TKR with a comparable efficacy and safety profile.
PMS38 ECONOMIC ANALYSIS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR KNEE REPLACEMENT IN SPAIN

PMS39 SEQUENTIAL COST-EFFECTIVENESS MODELLING OF DIFFERENT BIOLOGIC STRATEGIES IN RHEUMATOID ARTHRITIS IN TURKEY
Beresniak A 1 , Hamuryudan V 2 , Inanc M 2 , Pay S 3 , Yazici H 2 , Ozdedeli S 4 , Drost P 5 , Dupont D 6 1 Data Mining International, Geneva, Switzerland, 2 Istanbul University, Istanbul, Turkey, 3 Gülhane Military Medical Academy, Ankara, Turkey, 4 Bristol-Myers Squibb, Istanbul, Turkey, 5 Bristol-Myers Squibb International Corporation, Braine-l'Alleud, Belgium, 6 Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium OBJECTIVES: The management of moderate to severe rheumatoid arthritis includes the use of biologic agents. Modelling allows simulation of complex biologic treatment strategies after an insufficient response (IR) to previous biologic agents. The objective is to assess the cost-effectiveness of various biologic treatment sequences over two years according to the Turkish health care system using a public payer perspective. METHODS: Six treatment strategies using three successive biologic agents [etanercept (ETA), adalimumab (ADA), infliximab (INF), abatacept (ABA) or rituximab (RTX)], were modelled based on Turkish medical practice. Effectiveness was derived from published evidence as expected number of days in low disease activity state (LDAS). Biologic treatment was maintained for achieving LDAS or switched at each six months in case of IR. Total medical costs were estimated per level of disease activity over 6 months. Extensive probabilistic sensitivity analysis was performed. RESULTS: Considering an IR to 1 anti-TNF agent, the sequence ETA-ABA-ADA was more efficacious and cost-effective (102 days in LDAS; 496 TL per day in LDAS) over 2 years than the sequence ETA-RTX-ADA (82 days in LDAS; 554 TL per day in LDAS or 81 days in LDAS; 563 TL / day in LDAS based on RTX current reimbursement status). Considering an IR after 2 anti-TNF agents, the sequences ETA-ADA-ABA and ETA-INF-ABA were more efficacious and cost-effective (64 days in LDAS for both; 841 and 826 TL / day in LDAS, respectively) over 2 years than a sequence of anti-TNF agents only (32 days in LDAS; 1480 TL per day in LDAS). CONCLUSIONS: These simulations suggest that over two years of therapy, sequences including abatacept after an IR to one anti-TNF agent are more efficacious and cost-effective vs. similar sequences including rituximab. Sequences including abatacept after an IR to 2 anti-TNF agents also appear more effective and cost-effective than similar sequences composed of anti-TNF agents only.
PMS40
COST-EFFECTIVENESS SIMULATION MODEL OF BIOLOGIC STRATEGIES FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS BASED ON DISEASE ACTIVITY IN GERMANY
Beresniak A 1 , Baerwald C 2 , Zeidler H 3 , Gromnica-Ihle E 4 , Kruger K 5 , Neubauer AS 6 , Dupont D 7 , Merkesdal S 8 1 Data Mining International, Geneva, Switzerland, 2 Universitätsklinikum Leipzig AöR, Leipzig, Germany, 3 Rheumatologikum, Mitte, Hannover, Germany, 4 -, Berlin, Germany, 5 Praxiscentrum St. Bonifatius, Munich, Germany, 6 Bristol-Myers Squibb, Munich, Germany, 7 Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium, 8 Medizinische Hochschule Hannover, Hannover, Germany OBJECTIVES: Progressive Rheumatoid Arthritis (RA) usually requires different therapeutic options used sequentially in case of an insufficient response (IR) to previous agents. As clinical trials comparing biologic treatment sequences are lacking, simulation models inform on optimal treatment sequences and their cost-effectiveness. The objective was to assess the cost-effectiveness of different biologic treatment strategies based on levels of disease activity using the perspective of the German public payer. METHODS: A cost-effectiveness sequential model was developed based on RA treatment goals, using DAS28 scores as dichotomous endpoints: remission/no remission or Low Disease Activity State (LDAS)/no LDAS. Costs were estimated using a re-analysis of the published ' Hannover costing study'. Advanced simulations were conducted to assess the cost-effectiveness over 2 years of four sequential biologic strategies composed of anti-TNF agents, abatacept and rituximab, in patients with moderate to severe active RA and an IR to at least one anti-TNF agent. RESULTS: Medical costs for patients in LDAS, remission or in moderate to high disease activity were estimated at a3929 (SD 8566), a4853 (SD 13488) and a7017 per 6 months (SD 11813), respectively. Over 2 years, the sequence with abatacept after 1 anti-TNF agent appeared the most effective and cost-effective, vs. use after 2 anti-TNF agents (a633 vs. a1067/day in LDAS and a1222 vs. a3592/day in remission), and vs a similar sequence using rituximab (a633 vs. a728/day in LDAS and a1222 vs. a1812/day in remission). The sequence using a 3 rd anti-TNF agent was less effective and cost-effective than the same sequence using abatacept (a2000 vs. a1067/day in LDAS and a6623 vs. a3592/day in remission). CONCLUSIONS: Achieving LDAS or remission is associated with lower medical costs than high disease activity states. The results suggest that in patients with an IR to at least one anti-TNF agent, biologic sequences including abatacept appear more efficacious and cost-effective than similar sequences including rituximab or cycled anti TNF agents.
